This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perera, K. L. R. L.
Right arrow Articles by Mendis, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perera, K. L. R. L.
Right arrow Articles by Mendis, K.

 Previous Article  |  Next Article 

Infect Immun, April 1998, p. 1500-1506, Vol. 66, No. 4
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Baculovirus Merozoite Surface Protein 1 C-Terminal Recombinant Antigens Are Highly Protective in a Natural Primate Model for Human Plasmodium vivax Malaria

K. L. R. Lakshman Perera,1 Shiroma M. Handunnetti,1 Inge Holm,2 Shirley Longacre,2 and Kamini Mendis1,*

Malaria Research Unit, Department of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka,1 and Institut Pasteur, 75724 Paris, France2

Received 22 August 1997/Returned for modification 9 October 1997/Accepted 14 January 1998

A successful anti-blood stage malaria vaccine trial based on a leading vaccine candidate, the major merozoite surface antigen-1 (MSP1), is reported here. The trial was based on Plasmodium cynomolgi, which is a primate malaria parasite which is highly analogous to the human parasite Plasmodium vivax, in its natural host, the toque monkey, Macaca sinica. Two recombinant baculovirus-expressed P. cynomolgi MSP1 proteins, which are analogous to the 42- and 19-kDa C-terminal fragments of P. falciparum MSP1, were tested by immunizing three groups of three animals each with either p42, p19, or both together. The vaccines were delivered subcutaneously in three doses at 4-week intervals with complete and incomplete Freund's adjuvants. Very high antibody titers were obtained against both vaccinating antigens as measured by enzyme-linked immunosorbent assay (106 and above) and against whole parasites as measured by indirect immunofluorescence assay (>105), achieving, in most animals, about a 10-fold increase from the first to the last immunization. A blood stage challenge with P. cynomolgi parasites led, in three adjuvant-treated and three naive control animals, to blood infections which were patent for at least 44 days, reaching peak densities of 0.6 and 3.8%, respectively. In contrast, all except one of the nine animals in the three vaccinated groups were highly protected, showing either no parasitemia at all or transient parasitemias which were patent for only 1 or 2 days. When the three p19-vaccinated monkeys were rechallenged 6 months later, the protective efficacy was unchanged. The success of this trial, and striking analogies of this natural host-parasite system with human P. vivax malaria, suggests that it could serve as a surrogate system for the development of a human P. vivax malaria vaccine based on similar recombinant analogs of the P. vivax MSP1 antigen.

* Corresponding author. Mailing address: Malaria Research Unit, Department of Parasitology, Faculty of Medicine, P.O. Box 271, Kynsey Rd., Colombo, Sri Lanka. Phone: 94-1-688-660. Fax: 94-1-699-284. E-mail: knmendis{at}slt.lk.




This article has been cited by other articles:

  • Kocken, C. H. M., Remarque, E. J., Dubbeld, M. A., Wein, S., van der Wel, A., Verburgh, R. J., Vial, H. J., Thomas, A. W. (2009). Statistical Model To Evaluate In Vivo Activities of Antimalarial Drugs in a Plasmodium cynomolgi-Macaque Model for Plasmodium vivax Malaria. Antimicrob. Agents Chemother. 53: 421-427 [Abstract] [Full Text]  
  • Cheng, X.-J., Hayasaka, H., Watanabe, K., Tao, Y.-L., Liu, J.-Y., Tsukamoto, H., Horii, T., Tanabe, K., Tachibana, H. (2007). Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium falciparum. Infect. Immun. 75: 3614-3620 [Abstract] [Full Text]  
  • VALDERRAMA-AGUIRRE, A., QUINTERO, G., GOMEZ, A., CASTELLANOS, A., PEREZ, Y., MENDEZ, F., AREVALO-HERRERA, M., HERRERA, S. (2005). ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. Am J Trop Med Hyg 73: 16-24 [Abstract] [Full Text]  
  • Dutta, S., Kaushal, D. C., Ware, L. A., Puri, S. K., Kaushal, N. A., Narula, A., Upadhyaya, D. S., Lanar, D. E. (2005). Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys. Infect. Immun. 73: 5936-5944 [Abstract] [Full Text]  
  • Sachdeva, S., Ahmad, G., Malhotra, P., Mukherjee, P., Chauhan, V. S. (2004). Comparison of Immunogenicities of Recombinant Plasmodium vivax Merozoite Surface Protein 1 19- and 42-Kilodalton Fragments Expressed in Escherichia coli. Infect. Immun. 72: 5775-5782 [Abstract] [Full Text]  
  • Wipasa, J., Hirunpetcharat, C., Mahakunkijcharoen, Y., Xu, H., Elliott, S., Good, M. F. (2002). Identification of T Cell Epitopes on the 33-kDa Fragment of Plasmodium yoelii Merozoite Surface Protein 1 and Their Antibody-Independent Protective Role in Immunity to Blood Stage Malaria. J. Immunol. 169: 944-951 [Abstract] [Full Text]  
  • Dutta, S., Ware, L. A., Barbosa, A., Ockenhouse, C. F., Lanar, D. E. (2001). Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked Plasmodium vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed in Escherichia coli. Infect. Immun. 69: 5464-5470 [Abstract] [Full Text]  
  • Xuan, X., Larsen, A., Ikadai, H., Tanaka, T., Igarashi, I., Nagasawa, H., Fujisaki, K., Toyoda, Y., Suzuki, N., Mikami, T. (2001). Expression of Babesia equi Merozoite Antigen 1 in Insect Cells by Recombinant Baculovirus and Evaluation of Its Diagnostic Potential in an Enzyme-Linked Immunosorbent Assay. J. Clin. Microbiol. 39: 705-709 [Abstract] [Full Text]  
  • Wunderlich, G., Moura, I. C., del Portillo, H. A. (2000). Genetic Immunization of BALB/c mice with a Plasmid Bearing the Gene Coding for a Hybrid Merozoite Surface Protein 1-Hepatitis B Virus Surface Protein Fusion Protects Mice against Lethal Plasmodium chabaudi chabaudi PC1 Infection. Infect. Immun. 68: 5839-5845 [Abstract] [Full Text]  
  • Ahlborg, N., Ling, I. T., Holder, A. A., Riley, E. M. (2000). Linkage of Exogenous T-cell Epitopes to the 19-Kilodalton Region of Plasmodium yoelii Merozoite Surface Protein 1 (MSP119) Can Enhance Protective Immunity against Malaria and Modulate the Immunoglobulin Subclass Response to MSP119. Infect. Immun. 68: 2102-2109 [Abstract] [Full Text]  
  • Yang, C., Collins, W. E., Sullivan, J. S., Kaslow, D. C., Xiao, L., Lal, A. A. (1999). Partial Protection against Plasmodium vivax Blood-Stage Infection in Saimiri Monkeys by Immunization with a Recombinant C-Terminal Fragment of Merozoite Surface Protein 1 in Block Copolymer Adjuvant. Infect. Immun. 67: 342-349 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»